Key result
Dexmedetomidine as an anesthetic adjunct during off-pump coronary artery bypass surgery maintained a lower heart rate (68-85 vs 85-100 beats/min) and mean arterial pressure during distal anastomoses compared to midazolam.
Why the study?
The study was conducted to evaluate the hemodynamic profile of dexmedetomidine during induction and distal coronary anastomosis in patients undergoing OPCAB compared to institutional practice using midazolam.
Does dexmedetomidine improve hemodynamic stability compared to midazolam in patients undergoing elective OPCAB surgery?
RCT (n=50)
Computer generated randomization table
No
Does dexmedetomidine improve hemodynamic stability compared to midazolam in patients undergoing elective OPCAB surgery?
p-value: p=<0.05
Dexmedetomidine is a viable and hemodynamically stable anesthetic adjunct for patients undergoing elective off-pump coronary artery bypass surgery, effectively blunting the intubation response and maintaining lower heart rates during distal anastomosis.
No takes yet. Share an insight, caveat, or question.
May offer acceptable hemodynamic control as an OPCAB adjunct; leaves open whether it improves clinical outcomes over midazolam.
Virmani et al. (2021) conducted an RCT in Coronary Artery Disease requiring Off-Pump Coronary Artery Bypass Graft (OPCAB) Surgery (n=50). Dexmedetomidine vs. Midazolam (0.02mg/Kg) was evaluated on Hemodynamic profile (Heart rate and Mean Arterial Pressure) during induction and distal anastomosis (p=<0.05). Dexmedetomidine as an anesthetic adjunct during off-pump coronary artery bypass surgery maintained a lower heart rate (68-85 vs 85-100 beats/min) and mean arterial pressure during distal anastomoses compared to midazolam.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: